



**KOVE unleashes the potential of in-utero fetal surgery. Our innovation will reduce the risk of preterm birth by preventing amniotic sac rupture caused by those surgeries.**

Thanks to a new surgical technique called fetoscopy, it is possible to treat conditions inside the maternal womb during the pregnancy. To perform the surgeries, the amniotic sac is punctured, which makes it weak and results in fetal membrane rupture, leading to preterm birth in 30-80% of all fetoscopies. This is associated with a high rate of mortality and morbidity as well as heavy life-long disabilities with high costs associated to the treatment of those disabilities and the care of the premature babies.

KOVE developed a minimal invasive device to solve this problem faced by all fetal surgeons. The technique, developed after 15 years of clinical experience and research at the University of Zurich, seals and fixes the defect, reducing the risk for preterm birth after fetoscopies. With this device, KOVE will help save thousands of lives every year, give surgeons a new tool to safely develop further surgical procedures for new indications and save tremendous costs for the healthcare system, which spends ca. CHF 15'000 per week of prematurity.



**Innovation**

The device will allow surgeons to close the hole created during the surgery from the **inside** of the cavity, in a **minimally invasive** way, through the same catheter used for fetoscopy, using surgically **approved materials**. It is the result of **15 years of clinical** and scientific research and **8 years of PhD and PostDoc** research and development.

There is currently **no product available to fix the defect**. ChorioAnchor aims to squeeze the fetal membrane to the uterus with a degradable implant. ChorioAnchor is in early development and uses squeezing, which is not mechanical stable and doesn't seal.

**Proprietary IP**

- Patent on **fixing technology** filed in November 2021
- **Licensing agreement** signed in January 2021 with the University of Zurich for an **exclusive** use of both patents by KOVE medical AG
- Second patent on **fixing technology** filed in December 2022. Patent belongs to KOVE.

**Achievements**

**2021-2022**

- **50 days in vivo sheep study** showing fetal membrane closure. Mother and fetuses healthy, **defect closed**.
- Functional device model (3:1) and **final size construction** (1:1) with Zühlke engineering
- **Top 10 Medtech** start-up in >>Venture>> Competition
- Onboarding José Peiro, Femke Slagghekke and Nicolas Sananes, KOL in fetoscopy, as advisors.
- EIC Accelerator and Innosuisse grants awarded
- Assembly of first Prototype and test on pregnant sheep

**Earlier**

- **"Medtech company to watch"** by Venture Lab
- **8 years** R&D experience in fetal therapy
- Development of **standard ex vivo tests** to minimize in vivo trials



**Dr. Yannick Devaud**

Co-founder, CEO  
PhD in Bioengineering  
8 years in KOVE project  
R&D and Management



**Dr. Kurt Ruffieux**

Co-founder, CTO  
Founder Degr. Solutions  
EXIT to SunStar  
Strategy, Quality, IP



**Helena Tronnier**

Former Biotronik R&D  
Test Development  
Device Development

**Advisors**

**Prof. Femke Slagghekke**  
Fetal surgeon, Leiden

**Prof. Nicolas Sananes**  
Fetal Surgeon, Strasbourg

**Prof. Jose Peiro**  
Fetal surgeon, Cincinnati

**Arik Zucker**  
Business Advisor

**Lancelot Marx**  
Strategic Investment Advisor

**Scientific collaborators**

**University and University Hospital of Zurich**  
Fetoscopic surgery, animal studies, biological studies

**ETH Zurich**  
Mechanical testing



## Market

Globally, 6'000 fetoscopies are done yearly to treat Spina Bifida, Twin-to-Twin Transfusion syndrome (TTS), Congenital Diaphragmatic Hernia (CDH) and Congenital heart diseases (CHD) in **120 fetal treatment centers worldwide**. Providing a safer procedure will enable treating fetuses **earlier**, increasing the chance of **recovery**. It will also help clinicians employ fetoscopy **more often**. In 10 years, with the multiplication of fetal treatment centers and the establishment of fetoscopy as standard procedure, we estimate that **20'000** (serviceable market) of the **250'000** disabled fetuses that have access to fetoscopy (total potential patient population) could be treated, which represents **CHF 80 million of potential revenue**. **KOVE's aim is to serve roughly 30% of this market by 2030 and reach potential sales of CHF 30 million per year.**

